


PHARMACEUTICAL 2020

immun•gen

ImmunoGen Inc. Rank 187 of 362



PHARMACEUTICAL 2020

ImmunoGen Inc. Rank 187 of 362

immun•gen

The relative strengths and weaknesses of ImmunoGen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoGen Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 91% points. The greatest weakness of ImmunoGen Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is -185%, being 118% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	208,898
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	77,410
Liabilities, Non-Current	149,628
Other Assets	19,371
Other Compr. Net Income	0
Other Expenses	38,407
Other Liabilities	84,345
Other Net Income	5,014
Property and Equipment	6,993
Research and Development	114,522
Revenues	82,271
Selling, General and Administrative Expense	38,489

Output Variable	Value in 1000 USD
Assets	235,262
Liabilities	311,383
Expenses	191,418
Stockholders Equity	-76,121
Net Income	-104,133
Comprehensive Net Income	-104,133
Economic Capital Ratio	-185%